2604
0
Loading version...
🔄 Update App
🔍 Check for Updates
Test Notification
🔔 Enable Notifications
📰 Fetch NHK News
🚀 Fetch TechCrunch News
🧪 Experiment
📰 Article Management
📚 Reading List
🎤 Speaking List
📊 Statistics
💻 Software Statistics
Push Admin
Edit Reading
Back to List
Basic Information
Title
Please enter a title.
URL
Please enter a valid URL.
Date
カテゴリID
画像ファイル名
統計情報
単語数:
143語
読了回数:
0回
作成日:
2023/08/22 08:44
更新日:
2025/12/09 00:49
本文
本文
An expert panel at Japan's health ministry has approved a new drug to treat Alzheimer's disease. It is the first time that the panel has endorsed an Alzheimer's drug that targets a specific cause of the disease. The experts made the decision at a meeting on Monday. They said they have confirmed the effectiveness of the drug named lecanemab, which was jointly developed by Japanese firm Eisai and its US partner Biogen. The experts also said there are no serious safety concerns. The drug is designed to slow the progression of the disease by reducing the accumulation of amyloid beta protein in the brain. Eisai applied for the ministry's approval in January. The ministry designated the drug as an item that should be given screening priority. The drug can be produced and sold in Japan after it is granted the ministry's formal approval.
本文を入力してください。
メモ
メモ・感想
キャンセル
更新
Debug Info:
Saved State:
-
Redirected Flag:
-
Current URL:
-
Refresh
Close
Debug
Send Report
Send Report
Draw Arrow
Clear
Message:
Cancel
Send
